CL2014002956A1 - Composicion farmaceutica ocular que comprende particulas recubiertas de dimension menor a 1 micron, con un nucleo que comprende etaboato de loteprednol y un recubrimiento con modificadores de superficie; y uso para tratar la inflamacion, degeneracion macular, edema macular u otro trastorno del ojo. - Google Patents

Composicion farmaceutica ocular que comprende particulas recubiertas de dimension menor a 1 micron, con un nucleo que comprende etaboato de loteprednol y un recubrimiento con modificadores de superficie; y uso para tratar la inflamacion, degeneracion macular, edema macular u otro trastorno del ojo.

Info

Publication number
CL2014002956A1
CL2014002956A1 CL2014002956A CL2014002956A CL2014002956A1 CL 2014002956 A1 CL2014002956 A1 CL 2014002956A1 CL 2014002956 A CL2014002956 A CL 2014002956A CL 2014002956 A CL2014002956 A CL 2014002956A CL 2014002956 A1 CL2014002956 A1 CL 2014002956A1
Authority
CL
Chile
Prior art keywords
etaboate
loteprednol
nucleus
micron
coating
Prior art date
Application number
CL2014002956A
Other languages
English (en)
Inventor
Alexey Popov
Elizabeth M Enlow
Hongming Chen
Original Assignee
Kala Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48464113&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014002956(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kala Pharmaceuticals Inc filed Critical Kala Pharmaceuticals Inc
Publication of CL2014002956A1 publication Critical patent/CL2014002956A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CL2014002956A 2012-05-03 2014-10-30 Composicion farmaceutica ocular que comprende particulas recubiertas de dimension menor a 1 micron, con un nucleo que comprende etaboato de loteprednol y un recubrimiento con modificadores de superficie; y uso para tratar la inflamacion, degeneracion macular, edema macular u otro trastorno del ojo. CL2014002956A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261642313P 2012-05-03 2012-05-03
US201261642261P 2012-05-03 2012-05-03
US201261738949P 2012-12-18 2012-12-18
US201361784701P 2013-03-14 2013-03-14

Publications (1)

Publication Number Publication Date
CL2014002956A1 true CL2014002956A1 (es) 2015-10-02

Family

ID=48464113

Family Applications (3)

Application Number Title Priority Date Filing Date
CL2014002956A CL2014002956A1 (es) 2012-05-03 2014-10-30 Composicion farmaceutica ocular que comprende particulas recubiertas de dimension menor a 1 micron, con un nucleo que comprende etaboato de loteprednol y un recubrimiento con modificadores de superficie; y uso para tratar la inflamacion, degeneracion macular, edema macular u otro trastorno del ojo.
CL2019003432A CL2019003432A1 (es) 2012-05-03 2019-11-25 Composición farmacéutica oftálmica que comprende nanopartículas mucopenetrantes, cuyo núcleo comprende un agente activo farmacéutico seleccionado entre un inhibidor de ciclooxigenasa (cox) o un fármaco antiinflamatorio no esterioidal (aine), y está recubierto con un polímero modificador de superficie; y uso para tratar un trastorno del ojo (divisional de solicitud cl 2956-2014).
CL2019003433A CL2019003433A1 (es) 2012-05-03 2019-11-25 Composición farmacéutica oftálmica que comprende nanopartículas mucopenetrantes, cuyo núcleo comprende un agente activo farmacéutico seleccionado entre un inhibidor de receptor tirosina quinasa (rtk), o un inhibidor de la angiogénesis, y está recubierto con un polímero modificador de superficie; y uso para tratar un trastorno del ojo (divisional de solicitud cl 2956-2014).

Family Applications After (2)

Application Number Title Priority Date Filing Date
CL2019003432A CL2019003432A1 (es) 2012-05-03 2019-11-25 Composición farmacéutica oftálmica que comprende nanopartículas mucopenetrantes, cuyo núcleo comprende un agente activo farmacéutico seleccionado entre un inhibidor de ciclooxigenasa (cox) o un fármaco antiinflamatorio no esterioidal (aine), y está recubierto con un polímero modificador de superficie; y uso para tratar un trastorno del ojo (divisional de solicitud cl 2956-2014).
CL2019003433A CL2019003433A1 (es) 2012-05-03 2019-11-25 Composición farmacéutica oftálmica que comprende nanopartículas mucopenetrantes, cuyo núcleo comprende un agente activo farmacéutico seleccionado entre un inhibidor de receptor tirosina quinasa (rtk), o un inhibidor de la angiogénesis, y está recubierto con un polímero modificador de superficie; y uso para tratar un trastorno del ojo (divisional de solicitud cl 2956-2014).

Country Status (13)

Country Link
US (4) US20130316006A1 (es)
EP (1) EP2844223A1 (es)
JP (3) JP6720443B2 (es)
KR (2) KR20150006869A (es)
CN (5) CN111714472A (es)
AU (3) AU2013256092B2 (es)
BR (1) BR112014027296B1 (es)
CA (1) CA2871748C (es)
CL (3) CL2014002956A1 (es)
HK (2) HK1208161A1 (es)
MX (2) MX373352B (es)
NZ (5) NZ742005A (es)
WO (1) WO2013166436A1 (es)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8889193B2 (en) 2010-02-25 2014-11-18 The Johns Hopkins University Sustained delivery of therapeutic agents to an eye compartment
US10307372B2 (en) 2010-09-10 2019-06-04 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
US9327037B2 (en) 2011-02-08 2016-05-03 The Johns Hopkins University Mucus penetrating gene carriers
RU2598627C2 (ru) 2012-01-19 2016-09-27 Дзе Джонс Хопкинс Юниверсити Композиции на основе наночастиц с улучшенным проникновением через слизистые оболочки
CN104363924B (zh) 2012-03-16 2018-04-17 约翰霍普金斯大学 用于递送hif‑1抑制剂的控制释放调配物
HK1206268A1 (zh) 2012-03-16 2016-01-08 The Johns Hopkins University 用於遞送活性成分的非線性多嵌段共聚物-藥物軛合物
US10864219B2 (en) * 2012-05-03 2020-12-15 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
WO2013166385A1 (en) 2012-05-03 2013-11-07 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
EP3808339B1 (en) 2012-05-03 2025-11-12 Alcon Inc. Pharmaceutical nanoparticles showing improved mucosal transport
HK1208161A1 (en) * 2012-05-03 2016-02-26 Alcon Inc. Pharmaceutical nanoparticles showing improved mucosal transport
EP2849728A1 (en) 2012-05-04 2015-03-25 The Johns Hopkins University Lipid-based drug carriers for rapid penetration through mucus linings
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
WO2014124006A1 (en) 2013-02-05 2014-08-14 The Johns Hopkins University Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
AU2014227737B2 (en) 2013-03-15 2018-05-17 KALA BIO, Inc. Meropenem derivatives and uses thereof
TWI686213B (zh) 2013-03-21 2020-03-01 美商優普順藥物公司美國分部 可注射持續釋放組合物及使用其治療關節之發炎及與發炎有關之疼痛之方法
EP3607941A1 (en) 2013-04-30 2020-02-12 Otitopic Inc. Dry powder formulations and methods of use
US9988386B2 (en) 2013-05-30 2018-06-05 Kata Pharmaceuticals, Inc. Compounds for treatment of diseases of abnormal angiogenesis or aberrant growth factors and uses thereof
CN106061261B (zh) 2013-11-01 2018-04-24 卡拉制药公司 治疗化合物的结晶形式及其用途
WO2015127368A1 (en) 2014-02-23 2015-08-27 The Johns Hopkins University Hypotonic microbicidal formulations and methods of use
AU2015223084B2 (en) 2014-02-25 2019-11-07 Achillion Pharmaceuticals, Inc. Compounds for treatment of complement mediated disorders
ES2924768T3 (es) * 2014-05-01 2022-10-10 Integral Biosystems Llc Sistemas autoensamblados adherentes a membrana para el tratamiento de trastornos oculares
KR101501217B1 (ko) * 2014-07-17 2015-03-10 최명 필러용 폴리디옥사논 입자의 제조방법
EP3179982B1 (en) * 2014-07-28 2023-07-19 Sun Pharma Advanced Research Company Ltd Method of increasing bioavailability and/or prolonging ophthalmic action of a drug
CN106794152A (zh) * 2014-08-13 2017-05-31 约翰霍普金斯大学 用于预防角膜同种异体移植物排斥和新生血管形成的载有糖皮质激素的纳米颗粒
BR112017006918A2 (pt) * 2014-10-09 2017-12-12 Distretto Tecnologico Sicilia Micro E Nano Sistemi S C A R L formulações nanoestruturadas para liberação de silibinina e outros ingredientes ativos para o tratamento de doenças oculares
US20170239331A1 (en) * 2014-10-15 2017-08-24 Rapid Pathogen Screening, Inc. Formulations for histatin protectives and therapeutics
TWI806150B (zh) 2014-11-07 2023-06-21 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
KR102511830B1 (ko) * 2014-11-25 2023-03-17 엑시모어 엘티디. 단일 및 다수 생체활성제를 전달하기 위한 조성물 및 방법
US10253045B2 (en) 2014-11-26 2019-04-09 Kala Pharmaceuticals, Inc. Crystalline forms of a therapeutic compound and uses thereof
US10174022B2 (en) 2014-12-10 2019-01-08 Kala Pharmaceuticals, Inc. 1-amino-triazolo(1,5-A)pyridine-substituted urea derivative and uses thereof
WO2016094617A1 (en) * 2014-12-11 2016-06-16 Phosphorex, Inc. Aqueous topical drug formulation with controlled release and increased stability
NZ733130A (en) 2014-12-15 2018-09-28 Univ Johns Hopkins Sunitinib formulations and methods for use thereof in treatment of ocular disorders
US11324800B2 (en) 2015-01-15 2022-05-10 Wellspring Ophthalmics, Inc. Aqueous suspensions of cyclosporin
US20200237859A1 (en) 2019-01-25 2020-07-30 Newport Research, Inc. Aqueous suspensions of cyclosporin
WO2016123125A1 (en) 2015-01-27 2016-08-04 The Johns Hopkins University Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces
KR101730399B1 (ko) 2015-04-13 2017-04-27 영남대학교 산학협력단 악시티닙을 포함하는 약물 전달체 및 이의 제조방법
MX393691B (es) 2015-06-06 2025-03-24 Cloudbreak Therapeutics Llc Composiciones y metodos para tratar pterigion.
TWI664965B (zh) * 2015-06-22 2019-07-11 新源生物科技股份有限公司 酪胺酸激酶抑制劑之眼用調配物、其使用方法、及其製備方法
KR101778004B1 (ko) * 2015-06-22 2017-09-15 (주) 에빅스젠 이마티닙을 유효성분으로 포함하는 안구 건조 질환 예방 및 치료용 약학 조성물
US10729663B1 (en) * 2015-08-21 2020-08-04 University Of South Florida Nanoparticles in thermoreversible gels for enhanced therapeutics
WO2017035355A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Ether compounds for treatment of medical disorders
AR105808A1 (es) 2015-08-26 2017-11-08 Achillion Pharmaceuticals Inc Compuestos de amida para el tratamiento de trastornos médicos
WO2017035361A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Disubstituted compounds for the treatment of medical disorders
WO2017035351A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of medical disorders
AR105809A1 (es) 2015-08-26 2017-11-08 Achillion Pharmaceuticals Inc Compuestos para el tratamiento de trastornos médicos
WO2017035357A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Phosphonate compounds for treatment of medical disorders
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
EP3340983B1 (en) 2015-08-26 2023-10-04 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
ES2908479T3 (es) 2015-08-26 2022-04-29 Achillion Pharmaceuticals Inc Compuestos para el tratamiento de trastornos inmunitarios e inflamatorios
EA037327B1 (ru) 2015-09-22 2021-03-12 Грейбуг Вижн, Инк. Соединения и композиции для лечения глазных расстройств
US10036135B2 (en) * 2015-10-23 2018-07-31 Philip S. Dunlap Methods and systems to contain pollution and hazardous environments (CPHE)
JP2018531951A (ja) 2015-10-27 2018-11-01 ユープラシア ファーマシューティカルズ インク． 局所麻酔薬の徐放性製剤
CN108472250A (zh) * 2015-10-30 2018-08-31 约翰霍普金斯大学 高分子量粘液穿透颗粒和致密涂层
BR112018009644A2 (pt) 2015-11-12 2018-11-06 Graybug Vision Inc micropartículas agregantes sólidas modificadas na superfície, material injetável, processo para preparação de micropartículas agregantes sólidas modificadas na superfície, método para tratamento de um distúrbio ocular, e, uso de micropartículas agregantes sólidas modificadas na superfície
CN119656170A (zh) 2016-06-02 2025-03-21 拨康视云生物医药科技(广州)有限公司 使用尼达尼布来治疗具有异常新生血管形成的眼病的组合物和方法
WO2018052053A1 (ja) * 2016-09-13 2018-03-22 協和発酵キリン株式会社 医薬組成物
WO2018053318A1 (en) * 2016-09-16 2018-03-22 Kala Pharmaceuticals, Inc. Particles, compositions, and methods for ophthalmic and/or other applications
WO2018053321A1 (en) * 2016-09-16 2018-03-22 Kala Pharmaceuticals, Inc. Particles, compositions, and methods for ophthalmic and/or other applications
IL303696B2 (en) 2017-03-01 2025-02-01 Achillion Pharmaceuticals Inc Aryl, heteroaryl and heterocyclic pharmaceutical compounds for the treatment of medical disorders
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
EP3589287B1 (en) 2017-03-01 2022-09-14 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for treatment of medical disorders
WO2018175268A1 (en) * 2017-03-19 2018-09-27 Biohealthways, Inc. Biodegrading implantable ocular sustained release drug delivery system
EP3600324A4 (en) 2017-03-23 2020-12-09 Graybug Vision, Inc. COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF EYE DISORDERS
CA3062904A1 (en) * 2017-05-08 2018-11-15 Inmed Pharmaceuticals Inc. Ocular drug delivery formulation
US11160870B2 (en) 2017-05-10 2021-11-02 Graybug Vision, Inc. Extended release microparticles and suspensions thereof for medical therapy
US20190038623A1 (en) 2017-08-02 2019-02-07 Achillion Pharmaceuticals, Inc. Therapeutic regimens for treatment of paroxysmal nocturnal hemoglobinuria
WO2019055028A1 (en) * 2017-09-15 2019-03-21 Kala Pharmaceuticals, Inc. PARTICLES, COMPOSITIONS AND METHODS FOR OPHTHALMIC APPLICATIONS AND / OR OTHER APPLICATIONS
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
MX2020002769A (es) 2017-09-22 2020-07-20 Otitopic Inc Composiciones de polvo seco con estearato de magnesio.
WO2019098393A1 (ja) 2017-11-15 2019-05-23 中外製薬株式会社 ポリエチレングリコールにより修飾されたヒアルロン酸誘導体
EP3728137A4 (en) 2017-12-22 2021-12-08 North Carolina State University POLYMERIC FLUOROPHORES, COMPOSITIONS INCLUDING THEM, AND THEIR PREPARATION AND USE PROCESSES
CN112533615A (zh) * 2018-05-02 2021-03-19 美国奥科视光有限公司 次氯酸基眼睑清洁剂
BR112021004263A2 (pt) 2018-09-06 2021-05-25 Achillion Pharmaceuticals, Inc. formas mórficas de danicopano
JP7443375B2 (ja) 2018-09-06 2024-03-05 アキリオン ファーマシューティカルズ， インコーポレーテッド 医学的障害の治療のための大環状化合物
WO2020069024A1 (en) 2018-09-25 2020-04-02 Achillion Pharmaceuticals, Inc. Morphic forms of complement factor d inhibitors
CN110664757B (zh) * 2018-11-19 2022-08-02 成都瑞沐生物医药科技有限公司 纳米晶滴眼剂、其制备方法及其应用
CN113195472A (zh) 2018-12-17 2021-07-30 艾其林医药公司 用于治疗补体介导的病症的靶向给药
WO2020198062A1 (en) 2019-03-22 2020-10-01 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement mediated disorders
US12496279B2 (en) 2019-04-11 2025-12-16 The Johns Hopkins University Nanoparticles for drug delivery to brain
US20230190725A1 (en) * 2019-04-29 2023-06-22 The Board Of Trustees Of The University Of Illinois Mek inhibitors for corneal scarring and neovascularization
EP3999153A4 (en) * 2019-07-16 2023-08-16 The Regents Of The University Of Michigan Composite drug particles and uses thereof
WO2021063813A1 (en) 2019-10-01 2021-04-08 Evonik Operations Gmbh Process for preparing nanoparticles in the form of a powder comprising a bio-resorbable polyester
EP4069220A4 (en) * 2019-12-04 2024-04-24 Restore Vision, LLC. OPHTHALMIC FORMULATIONS FOR THE TREATMENT OF PRESBYOPIA
JP2024515220A (ja) 2021-04-26 2024-04-05 セラニーズ・イーブイエイ・パフォーマンス・ポリマーズ・エルエルシー 高分子薬剤化合物の持続放出用の埋め込み型デバイス
CN113214419B (zh) * 2021-05-06 2022-10-25 温州医科大学附属眼视光医院 一种乳糖酸修饰的聚2-溴乙基丙烯酸酯及其制备方法与应用
CN113414049B (zh) * 2021-06-04 2023-04-18 圣托马斯先进材料公司 一种智能雾化器及其使用方法
US20230111190A1 (en) * 2021-09-14 2023-04-13 Nulixir Inc. Oral compositions with improved bioavailability and methods of making the same
US20250041214A1 (en) * 2021-12-16 2025-02-06 Alveolus Bio, Inc. Inhalable or ingestible lactic acid compositions for the treatment of chronic lung disease
CA3249880A1 (en) * 2022-01-24 2023-07-27 Celanese Eva Performance Polymers Llc IMPLANTABLE DEVICE FOR ADMINISTRATING A TYROSINE KINASE INHIBITOR
EP4509115A1 (en) * 2022-03-31 2025-02-19 Senju Usa, Inc. Medical material
WO2023235794A2 (en) * 2022-06-01 2023-12-07 The Trustees Of The University Of Pennsylvania Adhesive particles for active delivery
US20240197691A1 (en) * 2022-12-15 2024-06-20 Cn2 Therapeutics, Inc. Tacrolimus compositions and methods of use
WO2025146683A1 (en) 2024-01-03 2025-07-10 Lyotropic Delivery Systems Ltd. Topical formulations for delivery of an active compound to the back of the eye
CN118217236B (zh) * 2024-03-25 2025-04-11 山西锦波生物医药股份有限公司 一种含重组iii型人源化胶原蛋白的润眼液及制备方法
CN118490657B (zh) * 2024-05-15 2025-01-17 仁合熙德隆药业有限公司 瑞戈非尼片及其制备方法
CN119097710B (zh) * 2024-09-11 2025-09-02 山东大学齐鲁医院 Ape1抑制剂在制备治疗过敏性鼻炎药物中的应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5619321B2 (es) * 1971-09-22 1981-05-07
US5540930A (en) * 1993-10-25 1996-07-30 Pharmos Corporation Suspension of loteprednol etabonate for ear, eye, or nose treatment
ATE232087T1 (de) * 1997-10-27 2003-02-15 Merck Patent Gmbh Feste lösungen und dispersionen von eines schlecht wasserlöslichen wirkstoffes
US20050191359A1 (en) * 2001-09-28 2005-09-01 Solubest Ltd. Water soluble nanoparticles and method for their production
US7101576B2 (en) * 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
AU2003241478A1 (en) * 2002-06-10 2003-12-22 Elan Pharma International, Ltd. Nanoparticulate sterol formulations and sterol combinations
US20040208833A1 (en) * 2003-02-04 2004-10-21 Elan Pharma International Ltd. Novel fluticasone formulations
CA2540104A1 (en) * 2003-09-30 2005-04-07 Solubest Ltd. Water soluble nanoparticles comprising inclusion complexes
EP1701704A2 (en) * 2003-12-31 2006-09-20 Pfizer Products Inc. Solid compositions of low-solubility drugs and poloxamers
CA2600085A1 (en) * 2005-03-09 2006-09-14 Toray Industries, Inc. Microparticle and pharmaceutical preparation
DE102005011786A1 (de) * 2005-03-11 2006-09-14 Pharmasol Gmbh Verfahren zur Herstellung ultrafeiner Submicron-Suspensionen
US20070149480A1 (en) * 2005-12-23 2007-06-28 Alcon, Inc. PHARMACEUTICAL COMPOSITION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
US20070178051A1 (en) * 2006-01-27 2007-08-02 Elan Pharma International, Ltd. Sterilized nanoparticulate glucocorticosteroid formulations
US7691811B2 (en) * 2006-05-25 2010-04-06 Bodor Nicholas S Transporter-enhanced corticosteroid activity and methods and compositions for treating dry eye
CN101317847B (zh) * 2007-06-06 2010-10-13 深圳市瑞谷医药技术有限公司 一种眼用或耳鼻用药物组合物及其用途
CN101129385B (zh) * 2007-08-14 2010-07-21 山东博士伦福瑞达制药有限公司 含加替沙星和依碳酸氯替泼诺的眼用组合物及其制备方法
WO2009099942A2 (en) * 2008-01-31 2009-08-13 Alnylam Pharmaceuticals, Inc. Chemically modified oligonucleotides and uses thereof
TWI580441B (zh) * 2008-09-19 2017-05-01 愛爾康研究有限公司 穩定的藥學次微米懸浮液及其形成方法
BRPI1014854A2 (pt) * 2009-03-30 2016-05-03 Cerulean Pharma Inc "conjugados polímero-agente, partículas, composições, e métodos de uso relacionados"
US8889193B2 (en) * 2010-02-25 2014-11-18 The Johns Hopkins University Sustained delivery of therapeutic agents to an eye compartment
EA201390600A1 (ru) * 2010-10-22 2013-09-30 Байнд Терапьютикс, Инк. Терапевтические наночастицы с сополимерами с большим молекулярным весом
WO2012061703A1 (en) 2010-11-05 2012-05-10 The Johns Hopkins University Compositions and methods relating to reduced mucoadhesion
HK1208161A1 (en) * 2012-05-03 2016-02-26 Alcon Inc. Pharmaceutical nanoparticles showing improved mucosal transport

Also Published As

Publication number Publication date
HK1208161A1 (en) 2016-02-26
NZ728721A (en) 2018-05-25
JP6720443B2 (ja) 2020-07-08
CL2019003433A1 (es) 2020-05-08
KR102373259B1 (ko) 2022-03-17
HK1208382A1 (en) 2016-03-04
AU2020203052C1 (en) 2023-11-30
NZ742005A (en) 2019-04-26
CL2019003432A1 (es) 2020-05-08
AU2020203052B2 (en) 2023-06-29
CA2871748C (en) 2021-07-06
JP2020015758A (ja) 2020-01-30
BR112014027296B1 (pt) 2022-09-13
CN111700878A (zh) 2020-09-25
AU2013256092A1 (en) 2014-10-30
JP2021038251A (ja) 2021-03-11
AU2018201215A1 (en) 2018-03-08
CN111700879A (zh) 2020-09-25
US20180271782A1 (en) 2018-09-27
MX2014013315A (es) 2015-09-10
CN111700880A (zh) 2020-09-25
US20130316006A1 (en) 2013-11-28
US20130316001A1 (en) 2013-11-28
NZ741873A (en) 2019-04-26
EP2844223A1 (en) 2015-03-11
BR112014027296A2 (pt) 2017-07-18
MX2020007227A (es) 2020-10-08
AU2013256092B2 (en) 2017-11-23
JP2015519331A (ja) 2015-07-09
CN104661647A (zh) 2015-05-27
MX373352B (es) 2020-03-27
US20210052489A1 (en) 2021-02-25
JP7372897B2 (ja) 2023-11-01
NZ700875A (en) 2017-03-31
KR20210013339A (ko) 2021-02-03
AU2018201215B2 (en) 2020-02-13
WO2013166436A1 (en) 2013-11-07
CN111714472A (zh) 2020-09-29
NZ742004A (en) 2019-04-26
AU2020203052A1 (en) 2020-05-28
CA2871748A1 (en) 2013-11-07
KR20150006869A (ko) 2015-01-19

Similar Documents

Publication Publication Date Title
CL2014002956A1 (es) Composicion farmaceutica ocular que comprende particulas recubiertas de dimension menor a 1 micron, con un nucleo que comprende etaboato de loteprednol y un recubrimiento con modificadores de superficie; y uso para tratar la inflamacion, degeneracion macular, edema macular u otro trastorno del ojo.
MX384021B (es) Composiciones y metodos para aplicaciones oftalmicas y/u otras aplicaciones.
CL2013002134A1 (es) Composicion farmaceutica oftalmica de administracion topica que comprende un androgeno; y metodo para tratar una afeccion ocular resultante de una deficiencia de androgeno.
CL2013001982A1 (es) Metodo para reducir los niveles de glucosa y tratar trastornos del metabolismo de la misma; composicion farmaceutica que comprende metformina y otro agente antidiabetico o antiobesidad.
WO2014205389A8 (en) Nuclear transport modulators and uses thereof
CL2014001158A1 (es) Compuestos derivados de piperazina alquilados; composicion farmaceutica que los comprende; proceso para preparar la composicion farmaceutica; kit y uso en el tratamiento de trastornos inmunes, cancer, enfermedades cardiovasculares, inflamacion, entre otros.
PL3574897T3 (pl) Postać użytkowa o przedłużonym uwalnianiu zawierająca mikrocząstki białka polimerowego do stosowania w ciele szklistym oka w leczeniu naczyniowych zaburzeń oczu
CO6791573A2 (es) Sistema y métodos para el uso en línea del rastro social que afecta el rendimiento de los préstamos y la puntuación del crédito
IL235923B (en) Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical preparations thereof
HK1218621A1 (zh) 用於治疗慢性炎症和炎性疾病的组合物及方法
BR112014023405A2 (pt) nanopartícula de derivado de quitosana, composição compreendendo a nanopartícula e método in vitro para distribuir molécula de ácido nucleico a uma célula
BR112014030044A2 (pt) uma composição na forma de uma dispersão compreendendo uma lignina , um método para a manufaturação da mesma e utilização da mesma
AU347233S (en) Wipes dispenser
GT201500035A (es) Composición farmacéutica oral en forma de microesferas y proceso de elaboración
BR112014017481A8 (pt) formulação em pó seco para uso em um inalador de pó seco, inalador de pó seco e uso de uma formulação
AR086346A1 (es) Proceso para producir un material inorganico particulado
PH12016501072A1 (en) Composition for oral delivery of bioactive agents
CL2013003700A1 (es) Composicion farmaceutica oftalmologica topica que comprende regorafenib, el cual se encuentra suspendido en un vehiculo farmaceuticamente aceptable; procedimiento de fabricacion y su uso para tratar o prevenir un trastorno oftalmologico.
PT2900251T (pt) Novos extratos de cynara scolymus, coffea spp. e olea europaea para o tratamento da síndrome metabólica
CL2015000537A1 (es) Siarn y su uso en los métodos y composiciones para el tratamiento y/o prevención de enfermedades de los ojos.
SI2755669T1 (sl) Izvlečki cynare scolymus in njihova uporaba za zdravljenje presnovnega sindroma in dislipidemije
PT3411014T (pt) Novas composições tópicas compreendendo ácido úsnico e sua utilização em terapia
EP3291838A4 (en) Anionic nanoparticles for use in the delivery of anionic small molecule drugs
CL2015000538A1 (es) Uso de molécula de ácido nucleico interferente corta (siarn) para tratar trastorno ocular caracterizado por presión intraocular elevada; dispensador de la composición que comprende sirna; y kit que comprende dispensador e instrucciones.
GB2510477B (en) Formulations for use in the treatment of chronic fatigue and associated conditions, etc